Author Archives: Ana Pena, PhD

ReachBio Launches Screening Platform to Find New Therapies for SCD

ReachBio Research Labs has created a drug screening platform to discover therapeutic compounds that trigger the production of fetal hemoglobin (HbF) to treat sickle cell disease (SCD) and other blood disorders. SCD belongs to a group of inherited disorders known as hemoglobinopathies, primarily caused by mutations in…

FDA Grants Priority Review to Novartis’ Application for Crizanlizumab

The U.S. Food and Drug Administration (FDA) accepted Novartis’ Biologics License Application (BLA) seeking marketing permission for crizanlizumab (SEG101), a potential treatment for vaso-occlusive crises (VOCs) in people with sickle cell disease (SCD). The agency granted the file priority review, to accelerate the product’s evaluation. “The…